UKCPA Women’s Health Group
Masterclass Programme:

Epilepsy and infection during pregnancy and the peripartum period

Friday 9th June 2017

Royal Pharmaceutical Society,
East Smithfield, London
This full day event is aimed at both core advanced and specialist pharmacists with an interest in epilepsy and infection management in pregnancy.

The day will cover aspects of epilepsy and infection during pregnancy and the peripartum period. This will include the management of anti-epileptic drugs during pregnancy, the obstetric risks to women with epilepsy and the risks to the foetus and newborn resulting from exposure to anti-epileptic drugs, and the management of epileptic seizures during pregnancy and in labour. It will also cover the identification and management of maternal and neonatal sepsis, the management and pharmacological treatment of HIV positive women during pregnancy and the peripartum period, the implications of HIV diagnosis on obstetric and neonatal management, and the risks to the foetus and newborn from exposure to anti-retrovirals.

Attending this event will help you advance your professional practice and could be used as evidence in your RPS Faculty portfolio.

**SPEAKERS**

Nicky Moya, Directorate Pharmacist Neonatal and Women’s Services, Portsmouth Hospitals NHS Trust  
Christina Nurmahi, Women & Newborn Care Group Lead Pharmacist, University Hospital Southampton NHS Foundation Trust  
Ann Dougan, Specialist Pharmacist, Neurosciences/Surgery, Bart’s Health NHS Trust  
Kieran Hand, Consultant Pharmacist Anti-Infectives, University Hospital Southampton NHS Foundation Trust  
Jonathan Peters, Specialist Pharmacist Anti-Infectives (Previously Specialist Pharmacist HIV & Sexual Health), University Hospital Southampton NHS Foundation Trust

**PROGRAMME**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session title</th>
<th>Speaker</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>0915 to 0930</td>
<td>Registration and refreshments</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0930 to 0945</td>
<td>Welcome</td>
<td>Nicky Moya</td>
<td>Presentations</td>
</tr>
<tr>
<td>0945 to 1045</td>
<td>Session 1 Epilepsy in Pregnancy</td>
<td>Ann Dougan</td>
<td>Presentation</td>
</tr>
<tr>
<td>1045 to 1100</td>
<td>Refreshment break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1100 to 1130</td>
<td>Session 2 To change or not to change?</td>
<td>Ann Dougan</td>
<td>Interactive case discussion/small group case studies</td>
</tr>
<tr>
<td>1130 to 1230</td>
<td>Session 3 Infections in Pregnancy</td>
<td>Kieran Hand</td>
<td>Presentation</td>
</tr>
<tr>
<td>1230 to 1300</td>
<td>Lunch break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1330 to 1400</td>
<td>Session 4 Infections in Pregnancy cont.</td>
<td>Kieran Hand</td>
<td>Interactive case discussion or small group case studies</td>
</tr>
<tr>
<td>1400 to 1500</td>
<td>Session 5 HIV in Pregnancy</td>
<td>Jonathan Peters</td>
<td>Presentation</td>
</tr>
<tr>
<td>1500 to 1515</td>
<td>Refreshment break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1515 to 1545</td>
<td>Session 6 HIV in Pregnancy cont.</td>
<td>Jonathan Peters</td>
<td>Interactive case discussion or small group case studies</td>
</tr>
<tr>
<td>1545 to 1630</td>
<td>Open Forum (Opportunity for delegates to raise questions followed by closing remarks)</td>
<td>Nicky Moya / Christina Nurmahi</td>
<td>Possible topics</td>
</tr>
<tr>
<td>1630 to 16.45</td>
<td>Evaluation and Close</td>
<td>Nicky Moya</td>
<td></td>
</tr>
</tbody>
</table>
The learning outcomes for this event are met by means of lectures, small group discussions and case studies.

**LEARNING OUTCOMES**

At the end of this event, participants should be able to:

**Epilepsy in pregnancy**

Develop an understanding of the types of epilepsy in the general population and the implications of pregnancy on management of the condition; have an awareness of the differences in management of seizures due to epilepsy from those of other origins e.g. pre-eclampsia in pregnancy.

Describe the pharmacological and pharmacokinetic changes in drug handling of anti-epileptic drugs as a result of pregnancy; this includes an understanding of dosing and monitoring requirements for anti-epileptic drugs during the antenatal and peripartum period and how these may change as the pregnancy progresses.

Demonstrate an understanding of obstetric risks to women with epilepsy, risks to foetus and newborn resulting from exposure to anti-epileptic drugs, importance of pre-pregnancy counselling and strategies to reduce risk both during pregnancy and whilst breastfeeding.

Demonstrate knowledge of commonly used drugs in pregnancy that need to be viewed in light of the diagnosis (e.g. epileptogenic drugs such as pethidine, drugs which interact with enzyme inducing anti-epileptic drugs, etc).

Demonstrate awareness of optimum management of epileptic seizures during pregnancy and in labour.

Demonstrate an understanding of the considerations of suitable contraceptive methods for women with epilepsy.

**HIV in pregnancy**

Develop an understanding of the diagnosis, management and pharmacological treatment of human immunodeficiency virus (HIV) positive women during pregnancy and the peripartum period including late presenting women not on treatment; demonstrate knowledge of commonly used antiretroviral protocols in this group.

Demonstrate awareness of the British HIV Association (BHIVA) guidelines for management of women in pregnancy.

Demonstrate knowledge of the implications of HIV diagnosis on obstetric management i.e. antenatal care, mode of delivery, management of spontaneous rupture of membranes, intrapartum management.

Demonstrate knowledge of the implications of HIV diagnosis on neonatal management i.e. post-exposure prophylaxis, infant feeding, vitamin K administration, immunisation, infant testing.

Demonstrate understanding of risks to foetus and newborn from exposure to anti-retrovirals.

Demonstrates knowledge of contraceptive choices for women with HIV including awareness of transmission and drug interaction issues.
Sepsis in pregnancy

Demonstrate an understanding of the risks of infection during pregnancy and strategies to reduce risk e.g. vaccination

Demonstrate knowledge of the main infections occurring during pregnancy, at delivery and post-partum.

Demonstrate understanding of symptoms and signs of maternal sepsis and how to identify and monitor for these.

Demonstrate knowledge of the use of antimicrobials for caesarean section or gynaecological surgery including management of surgical site infections and surgical prophylaxis.

Demonstrate knowledge of pharmacological management of commonly incurred infections in pregnancy and in the peripartum period, taking into consideration the risks to the foetus and newborn.

Demonstrate knowledge of pre-emptive treatment of potential infections in the newborn.

Understand pathophysiology and risk factors for the development of neonatal sepsis (early and late onset), particularly Group B Streptococcus. Understand the mechanism of action, pharmacology and pharmacokinetic characteristics and clinical use of treatments for neonatal sepsis.

Demonstrate knowledge of dosing and monitoring requirements in pregnancy and in the newborn of antimicrobials with a narrow therapeutic index.

Fees:
UKCPA Members: £130.00   Non-Members: £199.00

Please note that materials presented/made available at this event remain the property of the speaker or their company. The UKCPA does not accept any responsibility for information or data presented or disseminated. Expert opinions and views expressed by presenters are their own and this does not necessarily reflect the opinion of other UKCPA members, or UKCPA as a whole.

UKCPA, Suite 1.2F, Lyn House, 39 The Parade, Oadby, Leicester, LE2 5BB
Telephone: 0116 2714894, Email: admin@ukcpa.com, Website: www.ukclinicalpharmacy.org